SCHEMBL6014572

SCHEMBL6014572

COCC1(c2ccc(N)cc2)CCC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SLC6A3 Q01959 10/20 0.37
SLC6A4 P31645 10/20 0.37
DPP4 P27487 1/20 0.36
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
SLC6A2 P23975 4/20 0.35
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP19A1 P11511 2/20 0.34
CYP17A1 P05093 1/20 0.34
CYP11A1 P05108 1/20 0.34
CYP3A4 P08684 1/20 0.34
TBXAS1 P24557 1/20 0.34
PMP22 Q01453 1/20 0.34
PDE4D Q08499 1/20 0.34
PDE3A Q14432 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6014687 0.96 POLB (0.48) POLBALDH1A1L3MBTL1SLC6A3SLC6A4
SCHEMBL6014717 0.95 ALDH1A1 (0.50) POLBALDH1A1L3MBTL1SLC6A3SLC6A4
SCHEMBL8351127 0.83 SLC6A4 (0.36) L3MBTL1SLC6A3SLC6A4HTR2CHTR2B
SCHEMBL2325066 0.81 CHRM2 (0.37) POLBALDH1A1L3MBTL1SLC6A3SLC6A4
SCHEMBL14359682 0.81 DPP4 (0.52) ALDH1A1L3MBTL1SLC6A3SLC6A4DPP4
SCHEMBL13363412 0.78 POLB (0.38) POLBSLC6A3SLC6A4DPP4HTR2C
SCHEMBL2636513 0.78 CHRM2 (0.40) POLBALDH1A1L3MBTL1SLC6A3SLC6A4
SCHEMBL2327941 0.77 KDM1A (0.43) ALDH1A1MAPK1CYP19A1CYP3A4
SCHEMBL2324456 0.76 GAA (0.41) POLBL3MBTL1SLC6A3SLC6A4HTR2C
SCHEMBL2324459 0.76 GAA (0.41) POLBL3MBTL1SLC6A3SLC6A4HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633712-B1 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2014-06-25 EP disclosed
US-7129252-B2 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2006-10-31 US disclosed
EP-1633712-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Chen, Guoqing Paul (US) 2006-03-15 EP disclosed
WO-2005000232-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2005-01-06 WO disclosed
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors TEK, FLT1, VEGFA POLB 4026/4885ALDH1A1 3087/4885L3MBTL1 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.